
Sign up to save your podcasts
Or


Send us a text
Carlos is the Founder of Lacerta Bio, Lacerta Bio is a pharmaceutical business development consultancy. We work with pharmaceutical, biotechnology, medical device, diagnostic, and other life science companies. We also work with venture capital and private equity firms that invest in these companies.
He is also the CEO of Connexin Therapeutics, Inc. an early-stage glaucoma drug developer. Who has the goal of developing and partner novel connexin inhibitors for retinal neuroprotection secondary to glaucoma and other ophthalmic disease conditions.
In this episode, we discuss his startup Connexin Therapeutics and how things are progressing for a startup that is focused on bringing a Glaucoma drug to market.
By Don Davis PhD, MBA5
1010 ratings
Send us a text
Carlos is the Founder of Lacerta Bio, Lacerta Bio is a pharmaceutical business development consultancy. We work with pharmaceutical, biotechnology, medical device, diagnostic, and other life science companies. We also work with venture capital and private equity firms that invest in these companies.
He is also the CEO of Connexin Therapeutics, Inc. an early-stage glaucoma drug developer. Who has the goal of developing and partner novel connexin inhibitors for retinal neuroprotection secondary to glaucoma and other ophthalmic disease conditions.
In this episode, we discuss his startup Connexin Therapeutics and how things are progressing for a startup that is focused on bringing a Glaucoma drug to market.

761 Listeners

824 Listeners

6,205 Listeners

29,196 Listeners

19 Listeners

20,221 Listeners

1,386 Listeners